• ABOUT THE SUMMIT •
Following year-on-year success, CHI presents the Eighth Annual Immunogenicity and Bioassay Summit 2016: 3 conferences, FDA presenters plus 40+ additional presentations, 15+ interactive breakout round table and panel discussions, short courses, exhibit/poster hall, and networking opportunities with 250+ delegates. Immunogenicity Prediction & Control is designed to help investigators design and select non-immunogenic products for early-stage decision making, while Immunogenicity Assessment & Clinical Relevance and Optimizing Bioassays for Biologics will enable investigators to overcome the complexities of immunogenicity assessment and bioassays, and develop programs that ensure their products are safe and efficacious, and satisfy regulatory requirements.Bookmark our website for forthcoming details.
“Program and participants first class.”
- Associate Director, Novo Nordisk
“Breakout interaction with FDA experts was very valuable.”
- Associate Director, Alexion Pharmaceuticals Inc.
“Interesting new data and very relevant to the field.”
- Senior Scientist, Process Development, Amgen, Inc.
“Provided good overview of current problems and progress in the field.”
- Scientist, Bioanalytical Sciences, Immunogen
“Congratulations on a very well put together conference.”
- Assistant Vice President, PfizerView more testimonials
250 First Avenue, Suite 300
Needham, MA 02494
Biological Therapeutic Products
Biomarkers & Diagnostics
Bioprocess & Manufacturing
Clinical Trials & Translational Medicine
Drug & Device Safety
Drug Discovery & Development
IT & Informatics
Technology & Tools For Life Science
Cambridge Healthtech Institute
Cambridge Innovation Institute